Lamivudine therapy in chronic hepatitis B causing severe hepatitis.
-
摘要: 研究拉米夫定服药后致重型肝炎的情况。 13例患者服用拉米夫定 3~ 2 3个月 ,检测服用前后肝功能、HBV复制的指标、HBVYMDD基序的变化。检测发现 13例患者服用拉米夫定后 ,胆红素明显上升 (P <0 0 1)。HBeAg、HBV -DNA变化明显 (P <0 0 1) ,死亡 5例。长期使用拉米夫定有致重型肝炎可能Abstract: To research for lamivudine therapy causing severe hepatitis. 13 cases lamivudine therapy 3-23 months, Testing liver function, HBV message, HBV-YMDD gene. After lamivudine therapy, 13 cases bilirubin were above normal (P<0.01) , HBeAg, HBV-DNA levels were less than that before the lamivudine therapy (P<0.01) , 2 cases have HBV-YMDD mutants, 5 death cases, 4 recovery cases, 1 disconnecting case, 3 cases in hospital now. Long term lamivudine therapy may cause severe hepatitis. The clinical physician must pay more attention to use lamivudine.
-
Key words:
- Lamivudine /
- Severe hepatitis
-
[1]赵伟, 刘伟, 刘全俊, 等.基因芯片检测拉米夫定治疗乙型肝炎病毒变异[J].中华肝脏病杂志, 2003, 1 (3) ∶178-179. [2]舒欣, 刘刚, 马会慧, 等.拉米夫定长期治疗复发病例中HBVYMDD基序的变化[J].中华传染病杂志, 2001, 19 (4) ∶245-246. [3]辛永宁, 孙樱, 张健, 等.拉米夫定对慢性乙肝患者T细胞亚群影响的研究[J].临床肝胆病杂志, 2002, 18 (3) ∶192-193. [4]陈紫榕.病毒性肝炎[M].北京:人民卫生出版社, 2002.377. [5]骆抗先.乙型肝炎基础和临床[M ].第2版, 北京:人民卫生出版社, 2001.410-411. [6]拉米夫定临床应用专家指导小组.2001年拉米夫定临床应用专家共识[J].中华肝脏病杂志, 2002, 10 (2) ∶157-158.
本文二维码
计量
- 文章访问数: 2162
- HTML全文浏览量: 22
- PDF下载量: 733
- 被引次数: 0